Skip to main content
Marina Konopleva, MD, Oncology, Houston, TX

MarinaYKonoplevaMD

Oncology Houston, TX

Hematologic Oncology

Physician

Dr. Konopleva is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Konopleva's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Education & Training

  • Texas Tech University Health Sciences Center at Lubbock
    Texas Tech University Health Sciences Center at LubbockResidency, Internal Medicine, 2005 - 2008
  • St Petersburg Medical State Academy
    St Petersburg Medical State AcademyClass of 1990

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2022 - 2026
  • TX State Medical License
    TX State Medical License 2009 - 2024
  • OK State Medical License
    OK State Medical License 2020 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2009

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic Leukemia  
    L Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
  • Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
    Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
  • Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
    Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
  • Join now to see all

Abstracts/Posters

  • Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia
    Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
    Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
    Marina Y Konopleva, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Metabolism and Hematologic Malignancies 
    60th American Society of Hematology Annual Meeting - 12/2/2018
  • Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Authored Content

  • A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
  • MCL-1 up-Regulation Through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML ModelsOctober 2017
  • Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
  • The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
  • Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
  • Targeting the Mitochondria Metabolism of T-ALL with Novel Mitochondrial Complex I Inhibitor IACS-010759October 2017
  • Join now to see all

Press Mentions

  • Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
    Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 8th, 2023
  • New Leukemia-Killing Compounds Discovered
    New Leukemia-Killing Compounds DiscoveredJuly 27th, 2022
  • Rice University, UT-MD Anderson Cancer Center Researchers Discover New Leukemia-Killing Compounds
    Rice University, UT-MD Anderson Cancer Center Researchers Discover New Leukemia-Killing CompoundsJuly 1st, 2022
  • Join now to see all

Professional Memberships